HER2靶向药物联合化疗治疗HER2阳性涎腺导管癌1例

doi:10.3969/j.issn.1005-4979.2020.03.013

《口腔颌面外科杂志》 ›› 2020, Vol. 30 ›› Issue (3): 191-194. doi: 10.3969/j.issn.1005-4979.2020.03.013

• 病例报告 • 上一篇

HER2靶向药物联合化疗治疗HER2阳性涎腺导管癌1例

王梓聿¹(), 衣晓丽², 袁胜利²()

¹ 青岛大学医学部
² 青岛市市立医院本部肿瘤二科，山东青岛 266012

收稿日期:2019-06-26 修回日期:2020-01-07 出版日期:2020-06-28 发布日期:2020-06-26
通讯作者: 袁胜利，教授. E-mail: a22631610@163.com
作者简介:
王梓聿（1992—），男，山东日照人，住院医师，硕士. E-mail: 463548270@qq.com

HER2 Targeted Drug Combined with Chemotherapy for Treatment of Advanced HER2 Positive Salivary Duct Carcinoma: a Case Report

WANG Ziyu¹(), YI Xiaoli², YUAN Shengli²()

¹ School of Medicine, Qingdao University
² The Second Department of Oncology, Qingdao Municipal Hospital, Qingdao 266012, Shandong Province, China

Received:2019-06-26 Revised:2020-01-07 Online:2020-06-28 Published:2020-06-26

摘要/Abstract

摘要：

人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）阳性涎腺导管癌（salivary ductal carcinoma，SDC）在临床上较少见。本文报道1例该病术后经辅助治疗后病情进展的患者，行HER2靶向药物治疗，效果显著。应用HER2靶向药物联合化疗治疗HER2阳性SDC的疗效可能较传统化疗法更具优势，但仍有待于大样本对照研究。

关键词: 涎腺导管癌, 人表皮生长因子受体2, 靶向治疗

Abstract:

Human epidermal growth factor receptor 2( HER2) positive salivary ductal carcinoma (SDC) is relatively rare in clinical practice. This article reports one patient, who had progressed after adjuvant therapy received HER2-targeted drug therapy, and the effect of HER2-targeted drug treatment was significant. The efficacy of HER2 targeted therapy combined with chemotherapy in the treatment of HER2-positive SDC may be more advantageous than traditional chemotherapy, but large-scale controlled studies are still needed.

Key words: salivary ductal carcinoma (SDC), human epidermal growth factor receptor 2 (HER2）, targeted therapy

中图分类号:

R782

王梓聿, 衣晓丽, 袁胜利. HER2靶向药物联合化疗治疗HER2阳性涎腺导管癌1例[J]. 《口腔颌面外科杂志》, 2020, 30(3): 191-194.

WANG Ziyu, YI Xiaoli, YUAN Shengli. HER2 Targeted Drug Combined with Chemotherapy for Treatment of Advanced HER2 Positive Salivary Duct Carcinoma: a Case Report[J]. 《Journal of Oral and Maxillofacial Surgery》, 2020, 30(3): 191-194.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2020/V30/I3/191

图/表 5

图1 2017-05-11患者胸部CT平扫结果显示双肺多转移瘤，大者约7 mm 注：A. 肺窗，病灶位于左肺上叶后段； B. 肺窗，病灶位于左肺上舌段；C. 纵隔窗，病灶位于左肺上叶后段；D. 纵隔窗，病灶位于左肺上舌段。

Figure 1 2017-05-11 chest CT scan images showing multiple metastatic tumors of both lungs, the big one measured 7 mm

图2 2017-07-06胸部CT平扫显示双肺多发转移瘤较前明显缩小注：A. 肺窗，病灶位于左肺上叶后段； B. 肺窗，病灶位于左肺上舌段；C. 纵隔窗，病灶位于左肺上叶后段；D. 纵隔窗，病灶位于左肺上舌段。

Figure 2 2017-07-06 chest CT scan images showing that multiple metastatic tumors significantly reduced in both lungs

图3 2018-11-13胸部CT增强结果显示双肺多发转移瘤较前明显增大，大者约15 mm 注： A. 肺窗，病灶位于右肺上叶内侧段、左肺上叶前段；B. 肺窗，双上肺多发转移瘤；C. 纵隔窗，病灶位于右肺上叶内侧段、左肺上叶前段；D. 纵隔窗，双上肺多发转移瘤。

Figure 3 2018-11-13 chest CT images showing that multiple metastatic tumors in lungs were significantly bigger than the former one, and the largest is about 15 mm

图4 2018-12-05胸部CT平扫结果示双肺多发转移瘤较前明显缩小注：A. 肺窗，病灶位于右肺上叶内侧段、左肺上叶前段；B. 肺窗，双上肺多发转移瘤；C. 纵隔窗，病灶位于右肺上叶内侧段、左肺上叶前段；D. 纵隔窗，双上肺多发转移瘤。

Figure 4 2018-12-05 chest CT scan images showing that multiple metastatic tumors in both lungs were significantly smaller than the former one

图5 2018-12-29胸部CT平扫增强结果示双肺多发转移瘤较前明显缩小注：A. 肺窗，病灶位于右肺上叶内侧段、左肺上叶前段；B. 肺窗，双上肺多发转移瘤； C. 纵隔窗，病灶位于右肺上叶内侧段、左肺上叶前段；D. 纵隔窗，双上肺多发转移瘤。

Figure 5 2018-12-29 chest CT scan images showing that multiple metastatic tumors in both lungs were significantly smaller than the former one

参考文献 12

[1]	Kikuchi Y, Hirota M, Iwai T, et al. Salivary duct carcinoma in the mandible: a case report[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, 103(3): e41-e46. doi: 10.1016/j.tripleo.2006.01.004 pmid: 17321438
[2]	Barnes L, Eveson J, Reichart P, et al. World health organization classification of tumours[J]. Ear Nose Throat J, 2005, 85(2):74. doi: 10.1177/014556130608500201 URL
[3]	Jaehne M, Roeser K, Jaekel T, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases[J]. Cancer, 2005, 103(12): 2526-2533. doi: 10.1002/cncr.21116 pmid: 15900577
[4]	孟庆国, 王佳雪, 王斯佳. 马来酸吡咯替尼对乳腺癌术后患者心脏功能的影响[J]. 医学信息, 2019, 32(2): 152-153.
[5]	Cornolti G, Ungari M, Morassi ML, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland[J]. Arch Otolaryngol Head Neck Surg, 2007, 133(10): 1031-1036. doi: 10.1001/archotol.133.10.1031 URL
[6]	Salovaara E, Hakala O, Back L, et al. Management and outcome of salivary duct carcinoma in major salivary glands[J]. Eur Arch Otorhinolaryngol, 2013, 270(1): 281-285. doi: 10.1007/s00405-012-1997-4 pmid: 22437251
[7]	Limaye SA, Posner MR, Krane JF, et al. Trastuzumab for the treatment of salivary duct carcinoma[J]. Oncologist, 2013, 18(3): 294-300. doi: 10.1634/theoncologist.2012-0369 pmid: 23429737
[8]	Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype[J]. Clin Cancer Res, 2004, 10(3): 944-946. doi: 10.1158/1078-0432.ccr-03-0253 pmid: 14871971
[9]	Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244(4905): 707-712. doi: 10.1126/science.2470152 pmid: 2470152
[10]	Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues[J]. Oncogene, 1990, 5(7): 953-962. pmid: 1973830
[11]	Prat A, Parera M, Reyes V, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy[J]. Head Neck, 2008, 30(5): 680-683. doi: 10.1002/hed.v30:5 URL
[12]	Ma F, Ouyang QC, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, phase II study[J]. J Clin Oncol, 2019, 37(29): 2610-2619. doi: 10.1200/JCO.19.00108 pmid: 31430226

选择文件类型/文献管理软件名称

选择包含的内容

HER2靶向药物联合化疗治疗HER2阳性涎腺导管癌1例

HER2 Targeted Drug Combined with Chemotherapy for Treatment of Advanced HER2 Positive Salivary Duct Carcinoma: a Case Report

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 12

相关文章 7

编辑推荐

Metrics

本文评价

[1]	郭伟. 口腔颌面头颈部恶性肿瘤靶向治疗临床应用述评[J]. 《口腔颌面外科杂志》, 2020, 30(3): 132-136.
[2]	张霖，王中和. 阿帕替尼联合替吉奥胶囊治疗T4N0M0舌鳞癌的疗效观察[J]. 《口腔颌面外科杂志》, 2018, 28(3): 157-161.
[3]	王中和. 靶向治疗：口腔颌面-头颈部癌综合治疗的治疗选项[J]. 《口腔颌面外科杂志》, 2017, 27(4): 229-.
[4]	李葵芳1，范德生2，刘晔1，范得泉3. 姜黄素对口腔鳞癌SCC-25细胞EGFR信号通路表达的影响[J]. 《口腔颌面外科杂志》, 2015, 25(5): 326-.
[5]	郭伟，宋浩. 口腔颌面-头颈黏膜黑色素瘤的诊治现状和进展[J]. 《口腔颌面外科杂志》, 2015, 25(2): 85-.
[6]	王中和. 口腔颌面-头颈恶性肿瘤治疗的新策略：放疗联合个体化靶向治疗[J]. 《口腔颌面外科杂志》, 2014, 24(5): 325-.
[7]	郭　伟. 晚期口腔颌面-头颈部鳞癌靶向治疗的进展浅析[J]. 《口腔颌面外科杂志》, 2012, 22(2): 77-81.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

HER2靶向药物联合化疗治疗HER2阳性涎腺导管癌1例

HER2 Targeted Drug Combined with Chemotherapy for Treatment of Advanced HER2 Positive Salivary Duct Carcinoma: a Case Report

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 12

相关文章 7

编辑推荐

Metrics

本文评价